Gilead Sciences, Inc. (GILD) Shares Sold by Parnassus Investments CA

Parnassus Investments CA decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,695,139 shares of the biopharmaceutical company’s stock after selling 769,306 shares during the period. Gilead Sciences makes up 6.2% of Parnassus Investments CA’s portfolio, making the stock its largest holding. Parnassus Investments CA owned approximately 1.43% of Gilead Sciences worth $1,514,680,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in GILD. Sanders Capital LLC acquired a new stake in Gilead Sciences during the third quarter worth $427,585,000. Renaissance Technologies LLC boosted its stake in Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after buying an additional 2,700,600 shares in the last quarter. Vanguard Group Inc. boosted its stake in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Gilead Sciences by 50.0% during the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after buying an additional 2,062,886 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after buying an additional 1,937,031 shares in the last quarter. Institutional investors and hedge funds own 75.94% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.90 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The stock has a market capitalization of $96,510.00, a PE ratio of 8.41, a P/E/G ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the business posted $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio is 23.66%.

A number of equities research analysts have weighed in on the stock. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday. Oppenheimer assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating on the stock. Mizuho lifted their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Leerink Swann lifted their price target on shares of Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research note on Thursday, October 5th. Finally, BMO Capital Markets decreased their price target on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $85.03.

In related news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last quarter, insiders sold 461,666 shares of company stock valued at $34,072,567. Corporate insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Sold by Parnassus Investments CA” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/01/05/gilead-sciences-inc-gild-shares-sold-by-parnassus-investments-ca.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply